The estimated Net Worth of Kleem Chaudhary is at least 566 千$ dollars as of 26 February 2021. Dr Chaudhary owns over 2,000 units of Checkmate Pharmaceuticals stock worth over 84,000$ and over the last 4 years he sold CMPI stock worth over 0$. In addition, he makes 482,098$ as Chief Bus. Officer at Checkmate Pharmaceuticals.
Dr has made over 3 trades of the Checkmate Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of CMPI stock worth 5,240$ on 26 February 2021.
The largest trade he's ever made was exercising 4,000 units of Checkmate Pharmaceuticals stock on 22 December 2020 worth over 10,480$. On average, Dr trades about 1,600 units every 13 days since 2020. As of 26 February 2021 he still owns at least 8,000 units of Checkmate Pharmaceuticals stock.
You can see the complete history of Dr Chaudhary stock trades at the bottom of the page.
Dr. Kleem Chaudhary Ph.D. is the Chief Bus. Officer at Checkmate Pharmaceuticals.
As the Chief Bus. Officer of Checkmate Pharmaceuticals, the total compensation of Dr D at Checkmate Pharmaceuticals is 482,098$. There are 1 executives at Checkmate Pharmaceuticals getting paid more, with Dr. James E. Wooldridge M.D. having the highest compensation of 536,319$.
Dr D is 45, he's been the Chief Bus. Officer of Checkmate Pharmaceuticals since . There are 5 older and no younger executives at Checkmate Pharmaceuticals. The oldest executive at Checkmate Pharmaceuticals, Inc. is Dr. Arthur M. Krieg, 64, who is the Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director.
Kleem's mailing address filed with the SEC is C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Checkmate Pharmaceuticals have traded over 15,801,789$ worth of Checkmate Pharmaceuticals stock and bought 928,470 units worth 13,457,615$ . The most active insiders traders include Holdings A/S Novo、Global Strategic Fund Ii L....、Michael Powell. On average, Checkmate Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of 1,077,132$. The most recent stock trade was executed by Global Strategic Fund Ii L.... on 13 May 2022, trading 131,650 units of CMPI stock currently worth 1,375,743$.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Checkmate Pharmaceuticals executives and other stock owners filed with the SEC include: